Furiex Wins Fast Track Designation from FDA

Furiex Pharmaceuticals' MuDelta program has been granted Fast Track designation by the FDA.

Furiex Pharmaceuticals' application for MuDelta, a novel diarrhea-predominant irritable bowel syndrome treatment currently in Phase II, has been granted Fast Track designation by the FDA.

The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

"We are extremely pleased our MuDelta program has been granted Fast Track designation by the FDA,” said June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex. “The agency recognizes a significant unmet need for new treatment of diarrhea-predominant irritable bowel syndrome. We believe we are making significant pro